ZURA a penny stock has catalysts- an FDA action is soon upcoming and an insider bought a lot
more shares. The 120-minute chart shows a solid trend up since earnings March 28th. This
pre-revenue company beat earnings with less cash burn than expected. Another earnings
report is about a month away. Price has settled to the support of the longest EMA line.
I see an opportunity here for a long trade toward the earnings in a month. The longer black RSI
line above the 50 level while the shorter green line shows the oversold undervalued condition
for an entry.